Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.
Conor Killmurray
Advertisement
Articles by Conor Killmurray
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5